Clinical efficacy of Tirellizumab combined with lenvatinib in the treat-ment of advanced liver cancer
10.12092/j.issn.1009-2501.2025.03.012
- VernacularTitle:替雷利珠联合仑伐替尼治疗中晚期肝癌的临床疗效分析
- Author:
Yuanyuan WU
1
;
Chenlu LI
1
;
Yan CHEN
1
;
Mengda CAO
1
;
Hua SHAO
1
Author Information
1. 东南大学附属中大医院药学部,南京 210009,江苏
- Publication Type:Journal Article
- Keywords:
tirellizumab;
renvastinib;
immuno-therapy;
targeted therapy;
clinical effect
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(3):392-397
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To investigate the efficacy and safety of checkpoint inhibitor lenvatinib combined with Tirelizumab in the treatment of advanced he-patocellular carcinoma(HCC).METHODS:A retro-spective analysis was performed on 52 patients with advanced HCC treated with Renvatinib,tirelli-zumab or their combination from January 2021 to December 2022 in Zhongda Hospital Affiliated to Southeast University,with disease progression,death and intolerance as endpoints.Efficacy was as-sessed according to RECIST 1.1 criteria and follow-up was conducted up to June 2023.The main end-points of the study were objective response rate(ORR),disease control rate(DCR),progression-free survival,PFS)and security.RESULTS:The combina-tion therapy significantly improved ORR and mPFS in patients compared with tirelizumab or lenvatinib monotherapy.Compared with single tirellizumab or lenvastinib,there was no significant difference in the adverse reactions associated with the combina-tion treatment,suggesting that the combination of the two was generally well tolerated and the side effects are controllable.CONCLUSION:Lonvastinib combined with tirelizumab is more effective in the treatment of HCC,can significantly prolong PFS,and is generally well tolerated,which may be a po-tential treatment for advanced HCC.
